Infants diagnosed with Fragile X syndrome face a future marked by cognitive decline, speech impairment, heightened anxiety, hyperactivity, irritability, and impulsivity. Current treatments are piecemeal and riddled with side effects.
Seropeuticsdevelops efficacious therapies addressing the needs of Fragile X syndrome, and has identified two promising candidates, SERx – 519 and SERx – 480, that ameliorate core symptoms while measurably reducing side effects.
Executive Chairman & CEO
Scientific Founder and Chief Scientist
For more information about Seropeutics, contact Donald Kiepert.